Accelerate to discover
Related topics
A carboxymethyl dextran-based polymeric conjugate as the antigen carrier for cancer immunotherapy
Sep 18, 2018
A polymeric conjugate, composed of a carboxymethyl dextran (CMD) as the backbone and ovalbumin (OVA) as a model foreign...
Adenovirus type B detection using the xxpress qPCR thermal cycler
Sep 17, 2018
The ultrafast xxpress qPCR thermal cycler through performing standard dilution series and multiplex qPCR experiments is...
BluePippin-DNA size selection for NGS with pulsed-field (100bp-50kb)
Sep 3, 2018
Highly sensitive detection of mutations in CHO cell recombinant DNA uses multi‐parallel single molecule real‐time DNA...
IncuCyte webinar: Live-cell analysis of cell subsets and heterogeneity
Sep 3, 2018
Discover the new IncuCyte S3 cell-by-cell analysis software module. The innovative module allow label free analysis to...
Diagnosis of Acute Cellular Rejection Using Probe-Based Confocal Laser Endomicroscopy in Lung
Sep 3, 2018
Mauna Kea Technologies announced the publication of a prospective multicenter study that demonstrates the potential of...
ACEA Biosciences introduces an exploratory xCELLigence RTCA S16 instrument
Aug 30, 2018
The company has just introduced the xCELLigence RTCA S16, which is the ideal entry level model for exploratory studies...
Register for Bionano genomics October 2018 user group workshop
Aug 27, 2018
Registration for Bionano’s fall user group workshop is now open. The fall session is being held at Bionano's San Diego...
Aug 23, 2018
The new X-RAD 160 qube is suitable for either mounting on the lab bench or mobile on an optional wheeled cart, allowing...
May 18, 2016
With the increasing need for new therapies for cancer, autoimmune disorders and Alzheimer’s disease, monoclonal antibodies are proving very successful due to their high affinity and specificity for their target antigens. In cancer, for example, their first use was as antagonists of oncogenic receptor tyrosine kinases, but today monoclonal antibodies have emerged as vehicles for the targeted delivery of potent chemotherapeutic agents and as powerful tools to manipulate anticancer immune responses. Currently,
more than 30 antibody therapeutics are marketed worldwide. Some analysts predict that, given the rate of current revenue growth and potential new approvals, the global market could reach $58 billion by 2016. In addition, there are hundreds of monoclonal antibody-based biologic drugs in various phases of clinical trials worldwide.
Get more info
Brand profile
IntelliCyt Corporation's high throughput flow technology is the first to enable screening suspension cells, beads, microbes and mixtures.
More info at:
www.intellicyt.com/
BioFocus newsletter
Register to receive Brand new technology development, Important product updates, Interesting scientific events and more!
BioTech a.s. © 2014
Designed & developed by imagineit
Technologies
